Piomic’s executive team and board exhibits over 100 years of combined experience in medical device commercialization. Our vision is to make long lives worth living. We believe life should not be defined by a medical condition. By developing a therapy that is safe and effective we hope to set a better future for patients in need.
Successful development and industrialization of a portable next generation product
Achieving MDD certification during exemption period with limited time and regulatory resources
Minimizing time to market and achieving rapid indication validation in major chronic wound types
We aim continually to raise the bar for clinical research and synthesize high quality clinical evidence to enable broad market adoption of our innovative wound care products. We partner and build relationships with highly reputable clinicians and academic institutions to maximize the positive impact of our products towards the patients and the medical community at large.
A high percentage of the population will experience a chronic wound during their lifetime in developed countries. This trend is amplified by the demographic shift, the ageing population and propagation of diabetes.
Estimated market size for the worldwide market encompassing traditional wound care products, active and passive dressings as well as advanced devices in 2019.
The market is growing steadily, driven by the ageing population and lifestyle diseases. Forecast period of 2019 – 2026
Estimated market size for premium and mid-tier segment of products that use physical stimuli or biological components to actively promote wound healing in 2019.
Estimated market size for medical devices such as NPWT, HBOT Devices, Ultrasonic Devices and other physical therapeutic products in 2019.
The homecare sector for advanced wound management is expected to increase by almost 20% globally. This significant rise in home care services is expected to drive the growth of wound care products in the future. Sufferers of chronic ulcers look for advanced solutions that require little maintenance and accelerate healing time. Patient-driven interest should expand purchases of products from retail and pharmacy outlets.
The prevalence of diabetes is expected to reach 333 million by 2025 globally. Diabetic foot ulcers are a common complication of diabetes and affect approximately up to 25% of the diabetic population. In addition, almost 70% of all amputations are performed on diabetics, and hence, it is very important to provide appropriate care for diabetic foot ulcers.
“Research has difficulties to create innovations for treatment of wounds that are hard to heal. The COMS® technology finally brings new and very promising therapeutic approach to the field.”
“Piomic was able to achieve their milestones even during extraordinary transformations within the MedTech industry. I am excited to support this dedicated founding team on their journey”
“I am excited to see the potential impact of the COMS® technology which should not only lead to significant increase in quality of life in patients with chronic wounds but also substantial savings from a healthcare payer perspective.”
The Swiss W. A. de Vigier award recognizes startups that have outstanding solutions and leadership personalities. Piomic is very proud to be among the winners of the W.A. De Vigier Startup Award 2019. See the public presentation of the award ceremony.
Contact me by filling out this form: